We conducted a secondary analysis of data from a trial of Lactobacillus rhamnosus GG (LGG) supplementation as a pilot study to assess whether LGG prevents infant colic. For the first 6 months of life, infants received a daily dose of 10 billion colony-forming units of LGG or a control (n = 184). We compared the likelihood of a diagnosis of colic before 4 months of age, based on parent-reported symptoms or a physician diagnosis of colic. Out of the 184 infants, 18 (9.8%) had colic. There were no differences between the 2 groups in the percentage of infants with colic based on symptoms (control 5.4% vs LGG 9.8%; P = 0.19); physician diagnosis (control 3.2% vs LGG 7.6%; P = 0.26); or either symptoms or diagnosis combined (control 6.5% vs LGG 13.0%; P = 0.13). In this pilot study, early infant LGG supplementation does not appear to prevent the later development of colic.
*Department of Pediatrics
†Department of Epidemiology and Biostatistics
‡The Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA.
Address correspondence and reprint requests to Michael D. Cabana, MD, MPH, 3333 California Street, Laurel Heights Bldg #245, San Francisco, CA 94118 (e-mail: email@example.com).
Received 19 October, 2017
Accepted 24 May, 2018
www.clinicaltrials.gov registration number: NCT00113659.
This study was funded by the National Institutes of Health (HL 080074) and the Clinical and Translational Science Institute (UL1 RR024131) at UCSF.
M.D.C. has served as a paid consultant for Biogaia AB (Stockholm, Sweden) and Nestle (Vevey, Switzerland). The remaining authors have no financial relationships relevant or conflicts of interest to this article to disclose.